Results of two independent German cohorts

Antje Fischer
Eva Fischer, MD
Matthias Möhlig, MD
Matthias Schulze, DrPH
Kurt Hoffmann, PhD
Martin O. Weickert, MD

Rita Schueler
Martin Osterhoff, PhD
Andreas F.H. Pfeiffer, MD
Heiner Boeig, PhD
Joachim Spranger, MD

Various cross-sectional studies suggest that a polymorphism (E23K) within the ATP-sensitive K⁺ channel KCNJ11 gene is associated with type 2 diabetes (1). However, only two prospective studies have addressed the relation between KCNJ11 E23K and type 2 diabetes, and these studies were intervention trials based on individuals with impaired fasting glucose and impaired glucose tolerance (2–4). With respect to functional effects, recent studies have been inconsistent regarding demonstration of a relation of the polymorphism with markers of insulin secretion (3,5,6), although in vitro studies clearly suggested a defect in insulin secretion (7–9). One study proposed a relation to glucagon response, while insulin secretion itself was not affected (10). However, the relation between polymorphism and insulin secretion might have been masked in some of those studies by differences of insulin sensitivity, and detailed analysis might thus require consideration of insulin sensitivity of the study participants, such as that given in the disposition index (11).

We investigated the effect of KCNJ11 E23K on diabetes risk within a prospective case-cohort study (n = 2,945) of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. We additionally tested the association with diabetes in a second independent cross-sectional study, the Metabolic Syndrome Berlin Potsdam (MeSyBePo) cohort, from the same geographical region (n = 1,891). Within this second study, the association between polymorphism and disposition index was additionally investigated.

RESEARCH DESIGN AND METHODS — We designed a case-cohort study within the EPIC-Potsdam study, a prospective cohort involving 27,548 Caucasian volunteers, mainly aged 35–65 years, from the general population (12–14). A total of 2,263 individuals were randomly selected for a subcohort. Because the subcohort is representative of the entire cohort at baseline, 68 incident type 2 diabetes cases belonged to the subcohort and 682 incident cases were identified in the remainder of the total cohort, the latter classified as external cases (external cases/random subcohort: age 54.59/49.50 years, 283/1,394 female and 399/869 male, BMI 30.41/25.95 kg/m², and mean follow-up 7 years) (15). We used all incident cases (internal and external cases) in Cox regression models accounting for the case-cohort design.

For confirmation of genetic association and additional analysis of diabetes-associated subtraits, the cross-sectional MeSyBePo study, with 1,891 subjects, was investigated. Details of recruitment and phenotyping (case/control subjects: age 59.57/50.63 years, 55.5/69.1% female and 44.5/30.9% male, and BMI 32.22/28.67 kg/m²) of study participants were also published recently (16). In all participants of MeSyBePo, a 75-g oral glucose tolerance test (OGTT) with insulin measurements was performed. Only individuals with normal glucose tolerance (n = 1,070) or confirmed type 2 diabetes (n = 324) were considered for analysis of association with type 2 diabetes. The association between the polymorphism and the disposition index was investigated only in individuals with normal glucose tolerance, impaired fasting glucose, or impaired glucose tolerance, since accepted markers of insulin sensitivity and secretion have been shown to be unreliable in patients with type 2 diabetes, especially in patients with antidiabetes treatment.

A euglycemic-hyperinsulinemic clamp was performed in a subset of 56 healthy control subjects. In these participants, the in vivo insulin sensitivity index (ISI) according to Stumvoll et al. (17) (ISI calculated as area under the curve [AUC] insulin/AUC glucose, which performed best in the study of Stumvoll et al. compared with a hyperglycemic clamp, was used to estimate insulin secretion. Correspondingly, the disposition index was calculated as...
KCNJ11 E23K, diabetes risk, and disposition index

Table 1—Relation between KCNJ11 E23K and diabetes in the prospective EPIC-Potsdam cohort and the cross-sectional MeSyBePo cohort and association with the disposition index in the cross-sectional MeSyBePo cohort

| Genotypes | EPIC-Potsdam cohort | MeSyBePo cohort | MeSyBePo disposition index |
|-----------|---------------------|-----------------|---------------------------|
|           | n_{subcohort}/n_{case} | OR (95% CI) | P | Mean ± SE |
| EE        | 913/257             | 1.052/326      | 0.281 | 3.64 ± 0.02 |
| EK        | 1/0                 | 1.25 (0.91–1.71) | 1.86 (1.03–3.35) |
| KK        | 986/99              | 0.034          | 2.85 (1.18–2.91) |
| OR (95% CI) | 1 (ref.)           | 1.13 (0.90–1.42) | 1.32 (0.97–1.79) |
| P         | 0.02                | 1.080          | 0.007 |
| MeSyBePo disposition index | 627 | 730 | 380 |

Data are adjusted for age, sex, and BMI. The subcohort of EPIC-Potsdam was representative for the entire cohort and thus included 68 incident type 2 diabetes cases. Those were considered as cases in Cox regression analysis. General linear model was calculated to investigate the effects of the polymorphism on continuous variables after adjustment for confounders (age, sex, and BMI). Relative risks (RRs) were calculated using Cox proportional hazards regression modified according to the Barlow method in EPIC-Potsdam. Unconditional logistic regression analysis was performed to estimate odds ratios (ORs) in MeSyBePo. Multiplicative interaction terms between genotype and age, sex, or BMI were used to analyze potential interactions of these variables and disease risk. A two-tailed α error <5% was considered significant.

RESULTS — In both studies, the KCNJ11 E23K polymorphism was found in Hardy-Weinberg equilibrium. In the prospective EPIC-Potsdam cohort, the polymorphism was associated with increased RR for type 2 diabetes after adjustment for age, sex, and BMI (Table 1), although point estimates reached no statistical significance. Results were not indicative of effect modification with age or BMI. However, in sex-specific subanalyses, we found a significant association among women with KK genotype (RR 1.92 [95% CI 1.21–3.04]), while no association was observed among men with KK genotype (0.96 [0.60–1.53], P for interaction 0.098). The association between KCNJ11 E23K and prevalent type 2 diabetes was significant in the MeSyBePo cohort (EK genotype: 1.32 [0.97–1.79]; KK genotype: 1.85 [1.18–2.91]) (Table 1). However, in some contrast to the results in the EPIC cohort, comparable point estimates were found among KK genotype women (1.85 [1.03–3.35]) and men (1.86 [0.92–3.76]).

Interestingly, analysis of subtraits in this second cohort additionally demonstrated an effect of the polymorphism on the disposition index. Thus, individuals with the EE genotype had a higher disposition index than those with the EK or KK genotype (crude model: EE 3.66 ± 0.02, EK 3.45 ± 0.02, and KK 3.36 ± 0.03; P = 0.003). This relation remained significant after adjustment for age, sex, and BMI (Table 1).

CONCLUSIONS — Data from one prospective observational study and one cross-sectional study basically confirm that KCNJ11 E23K is associated with an increased risk of type 2 diabetes in Caucasian individuals, particularly among women. A potential sex-specific effect should be further investigated in subsequent studies or meta-analyses. The association with the disposition index suggested that consideration of insulin sensitivity may be required to elucidate effects of KCNJ11 E23K on insulin secretion and may partially explain controversial results of previous studies.

Some limitations of this study should be mentioned. Although other polymorphisms in KCNJ11 and ABCC8 might be relevant in the relation to type 2 diabetes, this study focused exclusively on KCNJ11 E23K for the following reasons. First, a considerable number of previous cross-sectional studies demonstrated associations between this polymorphism and type 2 diabetes. Second, in vitro data suggested a functional relevance of this polymorphism. Third, covering the KCNJ11 and the associated ABCC8 gene with haplotype tagging SNPs would have required considerably larger cohorts to avoid an underpowered study. Although we aimed to investigate a clear a priori–defined hypothesis, we cannot exclude that other polymorphisms in the genomic region of KCNJ11 might confer the relation between KCNJ11 E23K and type 2 diabetes described here. Taken together, these data further support a role of KCNJ11 E23K in the pathogenesis of type 2 diabetes in Caucasian individuals.

Acknowledgments — J.S. is supported by the BMBF (PTJ-BIO/0313847A) and a Heisenberg-Professorship of the Deutsche Forschungsgemeinschaft (DFG SP716/2-1). This project has been funded by the BMBF (01GS0487) within the framework of NGFN2 (Neuronetz Adipositas).

References
1. van Dam RM, Hoebbe B, Seidell JC, Schaap MM, de Bruin TW, Feskens EJ: Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet Med 22:590–598, 2005
2. Latukainen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Kaininen-Knuutanniemi S, Tuomilehto J, Uusitupa M, Laakso M: Polymorphisms of the SUR1 (ABCC8) and Kir2.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89:6286–6290, 2004
3. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, Thoersteinsson B, Borgh-Johnsen K, Hansen T, Pedersen O: The E23K variant of Kir2.2 associates with impaired post–OGTT serum insulin response and increased risk
of type 2 diabetes. *Diabetes* 52:573–577, 2003

4. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D: Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. *Diabetes* 56:531–536, 2007

5. ’t Hart LM, van Haeften TW, Dekker JM, Bot M, Heine RJ, Maassen JA: Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K+ channel in the β-cell. *Diabetes* 51:3135–3138, 2002

6. Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Mills N, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA: Sequence variants in the pancreatic islet β-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. *Diabetes* 46:502–507, 1997

7. Riedel MJ, Steckley DC, Light PE: Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. *Hum Genet* 116:133–145, 2005

8. Tarasov A, Dusonchet J, Ashcroft F: Metabolic regulation of the pancreatic β-cell ATP-sensitive K+ channel: a pas de deux. *Diabetes* 53 Suppl 3:S113–S122, 2004

9. Schwanstecher C, Meyer U, Schwanstecher M: Kir6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic β-cell ATP-sensitive K+ channels. *Diabetes* 51:875–879, 2002

10. Tschrirter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E, Teigeler A, Haring H, Fritschke A: The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (Kir6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. *Diabetes* 51:2854–2860, 2002

11. Bergman RN, Ader M, Huecking K, Van Citters G: Accurate assessment of β-cell function: the hyperbolic correction. *Diabetes* 51 (Suppl 1):S212–S220, 2002

12. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. *Lancet* 361:226–228, 2003

13. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. *Diabetes* 52:812–817, 2003

14. Boeing H, Korffmann A, Bergmann MM: Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. *Ann Nutr Metab* 43:205–215, 1999

15. Schulze MB, Al-Hasani H, Boeing H, Fisher E, Doring F, Joost HG: Variation in the HHEX-IDE gene region predisposes to type 2 diabetes in the prospective, population-based EPIC-Potsdam cohort. *Diabetologia* 50:2405–2407, 2007

16. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, Pfeiffer AF, Spranger J, Thamer C, Haring HU, Fritschke A, Joost HG: An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. *Diabetes Care* 30:510–515, 2007

17. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. *Diabetes Care* 23:295–301, 2000

18. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Haring H, Fritschke A, Gerich J: Assessment of insulin secretion from the oral glucose tolerance test in white patients with type 2 diabetes. *Diabetes Care* 23:1440–1441, 2000